HCA Healthcare is the dominant US for-profit hospital operator, benefiting from sustained admissions growth, favorable payor mix shifts toward commercial, and operating leverage on labor cost normalization. Sun Belt geographic exposure aligns with US demographic migration trends. Capital returns are aggressive. Regulatory risk on 340B and Medicare site-neutral payments remains a watch item.
Thesis reviewed May 29, 2026
HCA Healthcare Inc. is headquartered in United States, which is currently showing moderate signals.
πΊπΈUnited States59NEUTRALView United States risk detail βπ₯Healthcare28NEUTRAL| Ticker | Company | Score | Gap | Signal Ξ | Action |
|---|---|---|---|---|---|
| TEVA | Teva Pharmaceutical Industries Ltd. | 32 | +9% | β3% | NEUTRAL |
| SYK | Stryker Corporation | 32 | +15% | β3% | EARLY |
| DHR | Danaher Corporation | 32 | +11% | β3% | EARLY |
| CVS | CVS Health Corporation | 32 | +15% | β3% | AVOID |
| ELV | Elevance Health Inc. | 32 | +7% | β3% | NEUTRAL |
| UNH | UnitedHealth Group Inc. | 32 | +16% | β3% | AVOID |
| TMO | Thermo Fisher Scientific Inc. | 32 | +11% | β3% | EARLY |
Investors who hold HCA may also have indirect exposure through these country funds.
HCA admissions growth +4% in Q1 with improving payor mix
HCA raises 2026 guidance on Sun Belt strength
Estimates Β· Yahoo Finance Β· Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Jared MoskowitzFL | Buy | $1kβ$15k | Jun 17, 26 | ||
| Alan Armstrong | Buy | $1kβ$15k | Mar 27, 26 |